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The proposed algorithm achieved superior classification and outperformed Random Forests which currently represents the state-of-the-art classification process. Finally, the in silico pipeline presented introduces a novel strategy for identifying drug combinations with high therapeutic potential. For the first time, we demonstrate that DLNN trained on a large pharmacogenomic data set can effectively predict the therapeutic response of specific drugs in specific cancer types, from a large panel of both drugs and cancer cell lines. These findings serve as a proof of concept for the application of DLNN to predict therapeutic responsiveness, a milestone in precision medicine.
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Predicting the clinical response to therapeutic agents is a major challenge in cancer treatment. Ultimately, the ability to generate genomic informed personalized treatment with high efficacy is dependent upon identifying molecular disease signatures and matching them with the most effective therapeutic interventions. While the advent of multiple platforms providing "omic" data permits scientists to dissect the molecular events that are known to drive carcinogenesis 1 and alter major downstream processes, such as gene expression 2 , effectively translating the growing wealth of 'οmic' data into a personalised treatment strategy required by precision medicine, has been daunting and without noteworthy success 3 .
The successful identification of effective anti-cancer drugs has been primarily hindered by the lack of reliable preclinical models. Although cancer cell lines do not have the complexities of cancers, as they evolve in their normal tissue environment 4 , new technologies provide a wealth of information regarding the enormous degree of genomic heterogeneity across cancers, helping us to define the role that this diversity may play in understanding the wide variation in treatment responses 5 . In light of this newfound understanding of the significance of cancer genomic heterogeneity, recent efforts have resulted in large panels of cancer cell lines with information defining their genetic constitution, molecular markers and responsiveness to therapeutic compounds. This information allows us to identify the genomic determinants of the clinical response to specific drugs. It has been recently reported that oncogenic alterations in a large panel of tumors from 'The Cancer Genome Atlas' (TCGA) and other studies are conserved across the large panel cell-lines 6 . Three large scale cell panels containing pharmacogenomic data have been made available to the public domain: a) the 'Cancer Cell Line Encyclopedia' (CCLE) 7 , b) the Genomics of Drug Sensitivity in Cancer (GDSC) 8 and c) the NCI-60 9 . To identify predictive biomarkers, these consortia have analysed the molecular profiles of over 1000 cancer 5 cell lines and drug profiles for a large number of anticancer drugs.
The availability of these large data sets of cell-line panels along with the availability of new computational technologies has propelled a recent surge of interest to perform parallel analyses across cell lines, to extract information and define predictive biomarkers. However, while large data sets of pharmacogenomic profiles have been compiled with detailed molecular features and drug responsiveness, well validated computational approaches to define biologically relevant rules and generate algorithms that can accurately predict the responsiveness to a specific therapeutic drug are lacking. Although data mining algorithms are supposed to analyse large volumes of data and uncover hidden relationships of potential clinical significance, today's complex "omic" data sets have been proven too multi-dimensional to be effectively managed by classical Machine Learning algorithms. Deep Learning neural networks (DLNN), on the other hand, have the ability to "understand" complexity and multidimensionality and have been effectively applied in various fields (e.g. image analysis, text mining, etc.) with increased classification accuracy compared to classical computation methods 10 . DLNN is based on the modelling of high-level neural networks in flexible, multilayer systems of connected and interacting neurons, which perform numerous data abstractions and transformations 11 . In a recent surge of interest, DLNN has been effectively applied to extract features from various large and complex data sets, including predicting drug-target interactions 12 , drug toxicity in the liver 13 and pharmacological properties of drugs 14 , among others. Together, studies using the DLNN architecture demonstrate that it is well suited for complex biological data because it can automatically construct complex features and allows for multi-task learning 15 .
We designed a bioinformatics pipeline with multiple layers of molecular profiling information by 6 utilising the publically available pharmacogenomic profiles, in order to produce an expert system that, with demonstrated efficiency, could predict pharmacological responses to a large number of drugs over a broad panel of cancer-cell-lines ( Figure 1 ).
Specifically, we performed feature selection in the form of association rules and utilized the selected features to train multiple state-of-the art DLNN to predict pharmacological response in a blind set. The association rules are treated as a novel meta-dataset and are utilised in the form of paradigms for knowledge extraction. To our knowledge, this is the first time that the DLNN framework is systematically applied to predict drug efficacy against cancer.
Results

Dataset compilation:
To initiate a bioinformatics pipeline to predict drug response based on molecular profiles of multiple cancer cell types, we generated a large-scale pharmacogenomics dataset for 689 cancer cell lines and 139 anti-cancer drugs (Supplementary methods -Main Dataset). The new pharmacogenomics compilation was achieved by merging data from CCLP and GDSC. We used GDSC 8 as our drug response data source for 139 therapeutic compounds, which provided IC-50 values for each compound, as well as information on tissue origin.
Information on total gene mRNA expression, number of DNA copies and mutational status was obtained from the Cosmic Cell-line project (CCLP) 16 . CCLP was preferred as a data source since it provides profiles on 1,015 cancer cell lines and is not limited to the mutational status of genes (1,600), as is the case with CCLE. Although NCI-60 contains the largest number of therapeutic compounds tested for pharmacologic activity, it was excluded as a data source, as the 7 number of cell-lines presented is very low compared to the other resources used. This diminishes the effectiveness of NCI-60 to serve as a preclinical platform that can, at least, partially simulate clinically relevant tumour complexity ( Figure 2 ).
Association Rule Mining:
Given their molecular profiling data, both large cell-line panels (CCLE and GDSC) have been utilized in attempts to identify biomarkers for predicting drug response of specific cancer cell lines 7, 8 . Previous efforts to define biomarkers of drug response primarily utilize elastic net regression, a penalized linear modelling technique, to identify cooperative interactions among multiple genes and transcripts across the genome and define response signatures for each drug 16 . While efficient, this algorithm suffers certain limitations since when used for feature selection, as described in previous studies 7, 8 , the derived results are simple associations between a single gene and drug response. If, however, one wishes to explore the relevance of a more complex feature-space relationship (two or three-way interactions among simple features in all possible combinations) to the drug response, the process is convoluted. This is primarily due to the fact that these algorithms are supervised learning algorithms not being able to evaluate all possible combinations of a large number of features against a response variable. Associations are looked for only in the context of a predefined formula, such as Drug-Response, as compared to all genes being used as features (Drug-Response ~ All-Genes). The ability to evaluate all combinations of complex feature-tofeature interactions in relation to a response variable is not feasible within the design of the supervised learning algorithm without further implementation. Furthermore, multi-feature models generated by such algorithms are difficult to interpret in terms of biological relevance.
When utilised as a classifier to predict whether a sample will be resistant or sensitive to a drug given its molecular profile, the elastic net algorithm does not perform optimally. This is due to the fact that at the core of the elastic net algorithm lays linear regression, as opposed to non- 3. Rule Verification 3a. Paradigms: To validate the biological relevance of our statistically significant association rules, we examined whether known predictors of drug response are present in our rule set and whether drugs of a given target are present in sensitivity-associated rules along with the given target, if mutated or over-expressed.
Paradigm 1: We demonstrate that over-expressed NAD(P)H dehydrogenase 1 (NOQ1) and MDM2, a p53 inhibitor, which are known predictors of sensitivity for the drugs 17-AAG (Tanespimycin) and Nutlin-3, respectively 20, 21 , are present in our rule-set (Supplementary Table   1 Figure 1a) , while the PIK3CA top-lift clustering scheme revealed a significant and unique association of chronic myeloid leukaemia with sensitivity to the drug AZD8055, which is a dual inhibitor of mTORC1 and mTORC2
(Supplementary Figure 1b) . This "prediction" is confirmed in the literature, where AZD8055 was found to be effective in all patient samples, and within the six most selective drugs in all cases 23 .
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The rules clustering also revealed that AZD8055 would be effective in lymphoblastic leukaemia along with several other drugs, namely Rapamycin, MK-2206 and GDC-0941 (Supplementary Figure 1b) . Particularly, MK-2206, an Akt inhibitor, showed significant potency in treating T-cell acute lymphoblastic leukemia 24 , whereas GDC-0941, a pan class I PI3K inhibitor, was found to be effective against primary T-ALLs from wild-type and Kras(G12D) mice 25 .
Paradigm-3:
In order to mine the association rules for tissue specific drug sensitivity and resistance we created two subsets, both containing tissue type at the Left Hand Side (LHS) of the rules and drugs' sensitivity and resistance response-status at the Right Hand Side (RHS) of the rules. These subsets were clustered and visualized, as described above (k=50) ( Figure 4 , Table 2 ). Sensitivity of SCLC cells to ABT-263 is confirmed in the literature 26 , through the promotion of cell apoptosis. that in addition to Tissue=melanoma, also contain 'BRAF=Mut' at the LHS and Sensitivity to BRAF inhibitors at the RHS, confirming the fact that sensitivity to BRAF inhibitors is increased by the presence of the BRAF mutation.
Paradigm 5:
The following two paradigms indicate how the association rules, when allowing for interactions (2-way), can be used to gain further insight in the molecular mechanisms of drug resistance in SCLC and identify potential points of intervention.
Paradigm 5a: With the 1-way rules (Supplementary Table 1 Table   1 -2-way), we note that Growth hormone releasing hormone (GHRH) over-expression greatly increases the lift-value to 6.1, since resistance to Sunitinib is observed in 7 out of 13 SCLC celllines over-expressing GHRH (54%). Inhibiting GHRH activity using antagonists wields high anti-tumor activity by impending cell proliferation 28 . Furthermore GHRH activity has been linked to drug-resistance in triple negative breast cancer 29 . Moreover, the 2-way rules indicate that GHRH over-expression significantly contributes to the resistance of SCLC to CGP-082996 and XMD8-85, which are CDK4 and ERK5 inhibitors, respectively. By including interactions in 13 association rule mining, we are able to infer in this particular example that GHRH antagonists could be potentially used in combination therapy schemes with specific chemotherapeutic agents for the effective treatment of SCLC.
Paradigm 5b: With the 1-way rules (Supplementary Table 1 .
SCLC cell lines under-expressing SMAD3 clearly possess increased levels of BCL-2, which correlates well with the phenotype of resistance to a BCL-2 inhibitor, such as ObatoclaxMesylate. In this example, association rule mining precisely elucidated a specific part of the resistance mechanism of SCLC to BCL-family inhibitors, by highlighting a unique molecule that presents high mechanistic relevance to BCL-inhibition.
Prediction of Drug-Response 4a. Train & Test datasets for Machine Learning:
To predict drug response through machine learning, we split the main data-set into two subsets, referred to as training set and test set and This is a cluster ready framework, which allows for the machine learning part of our pipeline to be readily deployable to a high performance-computing environment. In order for machine learning to be able to perform well on the blind-set (test-set), it is critical to select only the most relevant features for training the classifier, for example features that are highly correlated with drug response. If a large number of irrelevant features are used for training, the classifier will be trained on noise, and although it will produce excellent results on the training set, it will perform poorly on the blind-set. This problem is referred to as over-fitting and in the application of 'omics' information, where the number of features (in our case, gene expression, mutation status, etc) vastly outnumbers the total number of cases, over-fitting is inevitable.
Previous reports have used elastic-net (as discussed above) 32 as a feature reduction technique. To address this challenge and select the most relevant features, we utilised the rule-set generated by Association Rule Mining, as performed on the training-set alone. (Supplementary Table 3 ). The deep learning classifiers (one classifier per drug and per drug-response-state) were trained on the training set using as training features the ones selected by the Association Rule Mining procedure and as response the respective drug-response. Each classifier's performance was then assessed on a blind-set (the test-set), where we provided only the specific features upon which the classifiers predicted the drug response, which was then compared to the actual drug-response value. We repeated the classification task utilising Random Forests, as the classification framework, which produced top prediction performance 17 , allowing us to compare the performance of the DLNNs with a state-of-the-art framework. Random Forests is a highly adaptive tree-based machine learning tool, that has been applied for prediction and classification for genomic data, and unsupervised learning 33 . The classification performance in all cases was quantified through ROC-Curve analysis. Technical details are presented in the respective Supplementary Methods Section.
By using the genes involved in the association-rules as features and the DLNN as a machinelearning framework, we constructed classifiers that would be able to predict whether a cell-line would be sensitive or resistant to a given drug based on its molecular profile. In agreement with a previous study 6 , since this is a dataset comprised of many cancer cell-lines from different tissues of origin, we observe that the vast majority of predictive features are gene expression levels. When we examine the two circular dendrograms, it is clear that they bear no-resemblance to each other meaning that the differentiated genes in the cell-lines that are resistant to a specific drug are diverse from the differentiated genes in the cell-lines that are sensitive to the same drug. To confirm this observation, we created a table describing the number of genes involved in sensitivity and resistance for each drug (Supplementary Table 5 , 'Genes overlap'). We were then able to calculate the overlap between all possible combinations as well as whether the magnitude of the overlap was random or over/under represented (p-value)(Supplementary Table 5 ), and allowed us to assign a p-value to each dendrogram relationship. We isolated all of the above information related to the sensitivity and resistance states only of each drug and report them in Supplementary Table 5 ('comparison sens & res per drug'). We note a very low overlap among the gene-sets involved in the sensitivity and resistance states of any given drug, indicating that the pathways involved in sensitivity and resistance for any given drug are diverse which is in perfect agreement with our prediction strategy, where we use different models from predicting sensitivity and resistance for each drug. When we closely examined the sensitivity dendrogram clustering structure, we note that it was highly relevant to the drugs' target ( Figure 6 ), indicating that drugs with the same target tend to cluster in close proximity to one another. Additionally, the sensitivity-status clustering appears to capture the broader relationships among the drugs. For instance, we observe that there is a branch populated not only by BRAF but also by MEK inhibitors which practically belong to the same pathway ( Figure 6 ) 36 . Likewise, we also note that PI3K, AKT and mTOR inhibitors were clustered together (Figure6). In contrast, when we examine the resistance dendrogram we note that clustering is less relevant to the drug targets in comparison to the sensitivity dendrogram meaning that the molecular cascades implicated in drug resistance are diverse from the ones that are being targeted by the drug. To determine whether drug clustering translates to highly correlated activity of closely clustered drugs (sensitivity dendrogram) across the cell-lines, we extracted the drug-to-drug rules from our total rule-set (Supplementary Table 6 , have shown to produce very promising results for melanoma treatment when combined together 35 .
Discussion
We present an in silico pipeline that utilises a large cancer cell-line dataset (689 cell lines) with diverse genomic features (>39,000 features) and responses to a diverse number of drugs (139), to extract knowledge in the form of easily interpretable rules and then by combining these rules with the sate-of-the-art Deep Learning framework to accurately predict drug responses. We also demonstrate that prediction of sensitivity and resistance responses must by handled by different models since the genes that drive these responses are diverse. Furthermore, we suggest a strategy, based on the drug sensitivity and resistance clustering to select the most potent candidates for drug-combination therapy.
Validation of the proposed algorithm, demonstrates high classification power with superior specificity and accuracy, compared to Random Forests which is considered the current state-ofthe-art process. In a personalised medicine setup, the molecular profile of the patient's tumour would be introduced in the pipeline and the later, as an expert system, would predict the drug response for a large screen of drugs allowing clinicians to select the best candidates for mono-or combination therapy. These candidates would then be tested on patient-derived primary 3D
cancer cell cultures 38 and/or on xenograft models 39 . The most efficient combination would then be applied in the form of a therapeutic scheme directly on the patient with constant monitoring for administration of personalised dosing.
The power of the pipeline lies on the efficiency, expandability and ability to create easily interpretable rules of the Association Rule mining algorithm, and to the ability of Deep Learning 21 to capture the complex heterogeneity of tumors. It can be further expanded by increasing the number of cancer cell-lines, including primary cancer cell-lines, as well as by increasing the number of therapeutic agents analysed by the system. Additionally, the system allows integration of other layers of 'omic' information, including meta-genomics, proteomics, phospho-proteomics, interactomics and metabolomics that will further enhance the prediction and drug-clustering schemes. We propose that our bioinformatics pipeline is expandable and effective utilising stateof-the-art algorithms such as Association Rule Mining and Deep Learning and can effectively be applied in the rapidly expanding "omics" era for devising personalised medicine schemes, as well as for drug discovery.
Figure Legends
Figure 1: Schematic representation of the study design and bioinformatics pipeline. The full data set was constructed using the GDSC and CCLP databases. Test data and training data sets were created using blocked randomisation. The use and progress of each data set is depicted by coloured arrows; full data set (red), test set (orange) and training set (green). The training and test set were used for deep learning and subsequent predicting of sensitivity and resistance. The full data set was used for clustering and dug synergy predictions. Unsupervised association rule mining was used for feature selection (from >39,000 features) of pharmacogenetic data.
Significant association rules were defined by dynamic thresh-holding. Rules derived from the training data set were used for deep learning. DLNN classifiers were applied for prediction of drug sensitivity and resistance. Extracted information was validated using the test set. Genes from rules derived from the full data set were used to construct a dissimilarity matrix based on the Jaccard index. Drugs were then clustered and predictions for drug synergy made. 26
Methods
All scripting, data-processing, statistical calculations have been performed with R-language for statistical computing 40 .
Datasets
The dataset compilation from 'Genomics of Drug Sensitivity in Cancer' (GDSC -release 5.0) and 'COSMIC Cell Line Project' (CCLP) was created by the R script "script_make_data.R".
Tissue of origin and drug response data were obtained from:
ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-
Gene mutation data was obtained from 'CosmicCLP_MutantExport.tsv', gene expression data was obtained from 'CCLP_CompleteGeneExpression.tsv' and copy number variation data was obtained from 'CCLP_CNV.tsv'. All the aforementioned files were downloaded from http://cancer.sanger.ac.uk/cell_lines/download.
More specifically, with respect to the molecular profiling data we included mutational status for 19426 genes, copy-number-variation status for the exons of 3744 genes and gene-expression status for 16444 genes. The gene mutation status is a factor consisting of 1 level, namely "Mut" that corresponds to all single point mutations apart from the silent ones. The copy-numbervariation status is a factor consisting of two levels, namely "Gain" and "Loss" for gains and losses, respectively, while the gene-expression status is a factor that also consists of two levels ("over" and "under") that correspond to z-scored gene expression levels greater and lower than two standard deviations from the mean, respectively. Finally the drug status is a factor consisting 27 of two levels, namely "Resistant" and "Sensitive" that correspond to z-scored IC-50 levels greater and lower than one standard deviation from the mean, respectively. The R-Data object containing the matrix is stored in the file MASTER_MATRIX.RData.
Association Rule Mining -Apriori Algorithm
To provide insights regarding the way the algorithm works we provide an example. Gene expression of Gene-A in our dataset has two levels, "over" and "under" Dynamic Thresholding:The Apriori algorithm was ran on a permuted version of our initial dataset (MASTER_MATRIX_PERMUTED.RData), which was produced by randomly shuffling each individual column of the dataset. The permutated matrix was produced with the script script_make_data.R. We initially ran the algorithm with the aforementioned support and confidence values on the permuted dataset and we determined the Lift threshold that would control the false discovery rate at less than 5%. We noted, however, that for each different set of support and confidence values belonging to our actual rules, there was a different lift threshold for FDR<5% if the Apriori algorithm had run on the permuted dataset with that set of support and confidence values as the minimum support and confidence parameters of the algorithm respectively. We therefore adjusted our thresholding determination with a method we call Dynamic Thresholding. Specifically, for every unique set of support and confidence values, we ran the Apriori algorithm on the permuted dataset using these values as the minimum support and confidence required by the algorithm, and we then determine the Lift threshold for which FDR=5%. After the completion of that process we evaluated each one of our actual rules based on its Lift value; if above of the specific threshold, the rule was accepted as significant, otherwise it was rejected. Both 1-way and 2-way rules where filtered keeping only the significant 29 rules (FDR<5%). The significant rules are available in Supplementary Table 1 . The rule-set constitutes a novel meta-data-set, which can be utilized for knowledge extraction as per the paradigms that follow in the current text.
The implementation of the Apriori & Dynamic Thresholding algorithms can be found in the script 'script_dynamic_thresholding.R'.
Group-wise rule visualization:
The group wise Association Rules visualization presented in the current study utilizes k-means clustering in order to visualize data with high dimensionality and high scarcity and are described in detail in Hahsler et al. (2011) 41 and is implemented in script 'script_rules_visualize.R'.
Prediction of drug-response
Training & Test Sets: The training and test sets were created by the R script "script_make_data.R". The original z-scored gene expression levels were restored to the total matrix and the Training and Test subsets were constructed by performing blocked randomization on the original matrix. The blocking factor was the tissue type, and two thirds of the cell lines from each tissue type were randomly assigned to the Training sets and the remaining one third to the Test set. The ratios were always rounded in favor of the Training set. If there were only two cases for a particular tissue type then they were evenly split between the Training and Test sets and if there was only one case, it was assigned only to the Training set. Additionally, the gene- Feature Selection: The Apriori -Dynamic Thresholding algorithm, as described above, ran on the Training set alone at minimum support and confidence levels of 0.58%, in order to produce rules having no feedback from the Test set used for measuring the classification performance (Supplementary Table 3 Table 4 -'Deep Learning'). For all the calculations of the aforementioned metrics apart from the AUC, the selected class-discriminating threshold was the one maximizing the Matthews correlation coefficient 43 .
Random Forests: Random Forest classifiers were constructed again using the H2O.ai platform.
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Each classifier consisted by number of trees equal to half the number of features utilized for training 44 . Class balancing and 5-fold cross validation was used. The exact parameters can be found in 'script_h2o_deep_learning_predictor_with_features_random_sampling_GE_NUM.R'. For
Random Forests we utilized exactly the same bagging scheme as for the DLNNs. The classification performance was measured as described in the previous section (Supplementary Table 4 -'Random Forests').
We did not use any further optimisation steps such as forward selection or backward elimination for model optimisation and hyper-parameter optimization to avoid over-fitting and hence report unbiased results.
Drug-clustering
Clustering were based upon the genes involved in the sensitivity or resistance state of each drug as extracted from the 1-way rules of the aforementioned Apriori algorithm (Supplementary   Table 5 -Genes). The top 100 rules ranked by support and top 100 rules ranked for Lift for each drug and response, were combined. These rules were then converted into a binary matrix (data/Binary Matrix.RData @ GitHub) where 1 denotes the presence of a rule and 0 denotes the absence (Binary Matrix.RData). From this matrix a dissimilarity matrix was calculated using the vegdist function and the Jaccard index 45 from the R package 'vegan' 46 . Hierarchical cluster analysis was then performed using the hclust function from the R package stats using the average clustering method 40 . The resulting cluster denrodrograms are displayed in a circular format using Table 5 -Genes). The gene-set overlap for all the combinations of the drug/drug-state pairs was also measured (Supplementary Table 5 -'Genes overlap'). The probability that an observed overlap between two drug/drugstate pairs was due to chance alone was evaluated with 100 rounds of Monte-Carlo simulation.
More particularly, for each round a number equal to the number of genes participating in the statistically significant association rules for each drug/drug-state was randomly sampled from the total pool of genes participating in all the significant association rules (18216 genes). The random sampling was weighted by the frequency of occurrence of each gene in the sum of the significant association rules; hence a gene participating in numerous rules will have a greater probability of being picked in comparison to a gene participating in just a few rules. At the end of each round, the overlap between the randomly sampled gene-sets of the particular drug/drugstate pair under examination was recorded. At the end of the 100-round Monte-Carlo simulation, the distribution of the 100 measured overlaps (which was found to be normal by the Kolmogorov-Smirnov test for normality) was utilized to calculate the p-value of the actual overlap between the particular drug/drug-state pair (Supplementary Table 5 -'p-values'). This pvalue represents the probability of the actual overlap to belong to the distribution of the randomly generated overlaps; hence the actual overlap being due to chance alone. If the actual overlap is located at the far right side of the random distribution the overlap is characterized as over-represented and statistically significant; hence non-randomly relevant. In contrast, if the 34 actual overlap is located at the far left side of the random distribution the overlap is characterized as under-represented and statistically significant; hence non-randomly distant (scripts/ script_measure_gene_overlaps_of_drugStates.R @ GitHub).
Data Availability
All scripts, data objects, figures and tables have been deposited and can be accessed at the public GitHub repository (folder: 'Vougas_DeepLearning') (https://github.com/kvougas/Vougas_DeepLearning)
